This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released late-stage clinical trial data for currently available disease-modifying therapies. Expert faculty Drs. Sarah Cuddy and Prem Soman break down how emerging evidence is reshaping treatment selection, including considerations for efficacy, safety, and patient-specific factors. The discussion highlights practical strategies for integrating these new findings into real-world clinical practice to optimize outcomes for patients with ATTR-CM.

This podcast is developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Bridge Bio.